High Tide Expands Global Presence with Acquisition of Remexian Pharma GmbH Majority Stake

High Tide Expands Global Presence with Remexian Acquisition

High Tide Inc., known as a prominent retail-focused player in the cannabis industry, has recently announced a significant business move—acquiring a 51% stake in Remexian Pharma GmbH for approximately €26.4 million. This acquisition is a pivotal step for High Tide, marking its strategic entry into the European market, particularly in Germany, which boasts the largest federally regulated cannabis sector on the continent.

Details of the Acquisition

The acquisition was finalized based on the terms outlined in the Acquisition Agreement, as disclosed in their press release dated August 14, 2025. The total enterprise valuation for Remexian is noted at €53.4 million, calculated to be 3.64 times the annualized Adjusted EBITDA for the six months ending March 31, 2025. The investment structure included cash, a loan, and High Tide shares, ensuring a balanced approach to funding the acquisition. Specifically, the purchase was funded through:

1. €7.65 million in cash
2. €7.65 million through a loan from the sellers, maturing on December 31, 2029, with a 7% annual interest rate
3. 5,864,373 High Tide shares valued at €11.1 million, based on their trading price before the acquisition date.

The shares issued in this deal come with a hold period of four months and one day, underscoring a cautious yet optimistic outlook on their valuation.

Growth Potential in Europe

According to Raj Grover, the Founder and CEO of High Tide, this acquisition is a transformational moment. It establishes High Tide’s footprint in Europe, transitioning it from a Canadian-centric company to a globally recognized cannabis enterprise. The acquisition not only diversifies High Tide’s revenue streams but also sets the stage for considerable expansion opportunities in Europe's tightly regulated cannabis markets. Grover emphasized that this strategic expansion aligns with their history of disciplined growth and commitment to generating free cash flow.

Remexian Pharma, as part of this integration, will benefit from High Tide’s established infrastructure, innovative retail strategies, and diversified cannabis product offerings which include everything from physical retail outlets to e-commerce platforms.

Future Options and Market Positioning

In addition to acquiring the initial stake, High Tide has secured a five-year option that allows them to acquire the remaining 49% of Remexian at an adjusted enterprise valuation base. This option provides High Tide with flexibility concerning future growth and strategic enhancement in operations. Furthermore, the owners of Remexian have agreed to a Put Option, allowing them to sell their remaining equity back to High Tide under specific conditions—creating a safety net for both parties involved.

These strategic moves highlight High Tide's ambition to solidify its leadership in the growing global cannabis market, especially in light of the projected growth trends in Europe, where medcinal cannabis regulations continue to evolve.

About High Tide

High Tide Inc. has become synonymous with innovation in the cannabis sector. The company operates various retail brands, with Canna Cabana being its flagship, recognized as one of the largest cannabis retail chains globally. Additionally, High Tide is innovating retail experiences through its automated technology, Fastendr, enhancing consumer interactions while browsing, ordering, and picking up products.

The diverse product lines include accessories through e-commerce platforms like Grasscity.com and support for essential cannabis-related services and products, which are fundamental to consumer engagement in an expanding market. As the industry matures, High Tide remains committed to leading the charge in fostering responsible cannabis consumption and business practice.

In conclusion, High Tide’s acquisition of Remexian represents a significant chapter in the company’s story, one that not only aims at market expansion but also reinforces their commitment to being a responsible leader in the evolving global cannabis landscape. The next several years will be critical as the company navigates its enhanced portfolio and potential market opportunities in Europe.